116 related articles for article (PubMed ID: 21222366)
1. Biomarkers for the diagnosis of thyroid cancer.
Sethi K; Sarkar S; Das S; Mohanty B; Mandal M
J Exp Ther Oncol; 2010; 8(4):341-52. PubMed ID: 21222366
[TBL] [Abstract][Full Text] [Related]
2. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application.
Saggiorato E; De Pompa R; Volante M; Cappia S; Arecco F; Dei Tos AP; Orlandi F; Papotti M
Endocr Relat Cancer; 2005 Jun; 12(2):305-17. PubMed ID: 15947105
[TBL] [Abstract][Full Text] [Related]
3. Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity.
Torregrossa L; Faviana P; Camacci T; Materazzi G; Berti P; Minuto M; Elisei R; Vitti P; Miccoli P; Basolo F
Hum Pathol; 2007 Oct; 38(10):1482-8. PubMed ID: 17597183
[TBL] [Abstract][Full Text] [Related]
4. Recent developments in the clinical application of thyroid cancer biomarkers.
Shibru D; Chung KW; Kebebew E
Curr Opin Oncol; 2008 Jan; 20(1):13-8. PubMed ID: 18043251
[TBL] [Abstract][Full Text] [Related]
5. CXC chemokine receptor 4 immunodetection in the follicular variant of papillary thyroid carcinoma: comparison to galectin-3 and hector battifora mesothelial cell-1.
Torregrossa L; Faviana P; Filice ME; Materazzi G; Miccoli P; Vitti P; Fontanini G; Melillo RM; Santoro M; Basolo F
Thyroid; 2010 May; 20(5):495-504. PubMed ID: 20450430
[TBL] [Abstract][Full Text] [Related]
6. The use of a combination of galectin-3 and thyroid peroxidase for the diagnosis and prognosis of thyroid cancer.
Weber KB; Shroyer KR; Heinz DE; Nawaz S; Said MS; Haugen BR
Am J Clin Pathol; 2004 Oct; 122(4):524-31. PubMed ID: 15487449
[TBL] [Abstract][Full Text] [Related]
7. Identification of immunohistochemical biomarkers for papillary thyroid carcinoma using gene expression profiling.
Murphy KM; Chen F; Clark DP
Hum Pathol; 2008 Mar; 39(3):420-6. PubMed ID: 18261626
[TBL] [Abstract][Full Text] [Related]
8. Immune characterization of thyroid neoplasm's and its variants using immunohistochemical markers: CK-19, Galectin-3 and Hector Battifora mesothelial-1.
Nehal S; Mittal R; Misra P; Rath J; Senapati U
Ann Diagn Pathol; 2022 Jun; 58():151931. PubMed ID: 35255428
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid.
El Demellawy D; Nasr AL; Babay S; Alowami S
Pathol Res Pract; 2009; 205(5):303-9. PubMed ID: 19153015
[TBL] [Abstract][Full Text] [Related]
10. Biomarker panel diagnosis of thyroid cancer: a critical review.
Griffith OL; Chiu CG; Gown AM; Jones SJ; Wiseman SM
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1399-413. PubMed ID: 18759692
[TBL] [Abstract][Full Text] [Related]
11. Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns.
Eszlinger M; Paschke R
Mol Cell Endocrinol; 2010 Jun; 322(1-2):29-37. PubMed ID: 20083161
[TBL] [Abstract][Full Text] [Related]
12. HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma.
Sack MJ; Astengo-Osuna C; Lin BT; Battifora H; LiVolsi VA
Mod Pathol; 1997 Jul; 10(7):668-74. PubMed ID: 9237176
[TBL] [Abstract][Full Text] [Related]
13. Tall cell variant of papillary thyroid carcinoma: Its characteristic features demonstrated by fine-needle aspiration cytology and immunohistochemical study.
Urano M; Kiriyama Y; Takakuwa Y; Kuroda M
Diagn Cytopathol; 2009 Oct; 37(10):732-7. PubMed ID: 19373912
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy.
de Matos PS; Ferreira AP; de Oliveira Facuri F; Assumpção LV; Metze K; Ward LS
Histopathology; 2005 Oct; 47(4):391-401. PubMed ID: 16178894
[TBL] [Abstract][Full Text] [Related]
15. The role of immunolocalization of CD57 and GLUT-1 in cell blocks in fine-needle aspiration diagnosis of papillary thyroid carcinoma.
Chandan VS; Faquin WC; Wilbur DC; Khurana KK
Cancer; 2006 Oct; 108(5):331-6. PubMed ID: 16944537
[TBL] [Abstract][Full Text] [Related]
16. Circulating thyroid cancer markers.
Gupta M; Chia SY
Curr Opin Endocrinol Diabetes Obes; 2007 Oct; 14(5):383-8. PubMed ID: 17940468
[TBL] [Abstract][Full Text] [Related]
17. [Cellular tumor markers in thyroid cancer].
Kopczyńska E; Kwapisz J; Junik R; Tyrakowski T
Pol Merkur Lekarski; 2007 Apr; 22(130):295-9. PubMed ID: 17684930
[TBL] [Abstract][Full Text] [Related]
18. Immunostaining of galectin-3 and CD44v6 using fine-needle aspiration for distinguishing follicular carcinoma from adenoma.
Maruta J; Hashimoto H; Yamashita H; Yamashita H; Noguchi S
Diagn Cytopathol; 2004 Dec; 31(6):392-6. PubMed ID: 15540177
[TBL] [Abstract][Full Text] [Related]
19. Molecular phenotyping of thyroid tumors identifies a marker panel for differentiated thyroid cancer diagnosis.
Wiseman SM; Melck A; Masoudi H; Ghaidi F; Goldstein L; Gown A; Jones SJ; Griffith OL
Ann Surg Oncol; 2008 Oct; 15(10):2811-26. PubMed ID: 18612701
[TBL] [Abstract][Full Text] [Related]
20. Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms.
Aron M; Kapila K; Verma K
Indian J Pathol Microbiol; 2006 Jul; 49(3):376-80. PubMed ID: 17001889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]